Published in J Pharmacol Exp Ther on September 01, 2002
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men | NCT00256256
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail (2008) 2.93
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut (2008) 1.56
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
Incretin-based therapies. J Diabetes (2012) 1.48
Retracted Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit. Br J Pharmacol (2012) 1.42
Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol (2006) 1.40
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation (2008) 1.40
Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab (2011) 1.40
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis (2010) 1.36
Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest (2013) 1.32
Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem (2003) 1.20
Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol (2010) 1.17
Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol (2012) 1.10
Therapy in the early stage: incretins. Diabetes Care (2011) 1.08
Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochim Biophys Acta (2010) 1.08
Retracted Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci (2007) 1.06
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs (2012) 1.05
Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med (2005) 0.99
GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab (2011) 0.99
Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One (2012) 0.98
Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem (2010) 0.97
Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmission. Neuropsychopharmacology (2014) 0.96
Bidirectional metabolic regulation of neurocognitive function. Neurobiol Learn Mem (2011) 0.95
New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol (2012) 0.95
The impact of dietary energy intake on cognitive aging. Front Aging Neurosci (2010) 0.94
A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets (2012) 0.93
Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci (2014) 0.93
Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) (2012) 0.93
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) (2012) 0.92
Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol (2011) 0.91
Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. Annu Rev Nutr (2014) 0.89
Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement (2014) 0.88
Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. J Diabetes Investig (2015) 0.87
GLP-1 improves neuropathology after murine cold lesion brain trauma. Ann Clin Transl Neurol (2014) 0.86
Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One (2013) 0.85
Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. Front Endocrinol (Lausanne) (2013) 0.83
Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats. Fluids Barriers CNS (2011) 0.83
Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol (2012) 0.83
Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury. PLoS One (2015) 0.83
Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons. BMC Gastroenterol (2012) 0.82
Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Sci OA (2015) 0.81
Parkinson's disease: an update on pathogenesis and treatment. J Neurol (2013) 0.81
Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J Parkinsons Dis (2013) 0.80
Exendin-4-loaded PLGA microspheres relieve cerebral ischemia/reperfusion injury and neurologic deficits through long-lasting bioactivity-mediated phosphorylated Akt/eNOS signaling in rats. J Cereb Blood Flow Metab (2015) 0.80
Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J Neurochem (2015) 0.80
Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS One (2012) 0.79
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev (2016) 0.78
GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol (2016) 0.78
Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development. J Neurosci Methods (2016) 0.77
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly? Drug Des Devel Ther (2014) 0.75
Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease. Front Aging Neurosci (2017) 0.75
Activation of GLP-1 Receptor Enhances Neuronal Base Excision Repair via PI3K-AKT-Induced Expression of Apurinic/Apyrimidinic Endonuclease 1. Theranostics (2016) 0.75
Insulin resistance in Alzheimer's disease. Transl Res (2016) 0.75
Incretins and the intensivist: what are they and what does an intensivist need to know about them? Crit Care (2014) 0.75
The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci (2016) 0.75
Decreased glucagon-like peptide-1 receptor immunoreactivity in the dentate granule cell layer from adult in the gerbil hippocampus. Cell Mol Neurobiol (2010) 0.75
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science (2005) 8.86
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A (2007) 4.62
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Superoxide flashes in single mitochondria. Cell (2008) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A (2007) 3.91
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 3.61
Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem (2002) 3.27
Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci (2008) 3.25
AGEMAP: a gene expression database for aging in mice. PLoS Genet (2007) 3.22
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci (2008) 3.11
Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc Natl Acad Sci U S A (2003) 2.82
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther (2006) 2.71
"Control" laboratory rodents are metabolically morbid: why it matters. Proc Natl Acad Sci U S A (2010) 2.50
Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem (2002) 2.45
Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus (2008) 2.44
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev (2008) 2.39
Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol Appl Pharmacol (2007) 2.37
Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A (2003) 2.35
Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med (2006) 2.32
Calcium orchestrates apoptosis. Nat Cell Biol (2003) 2.27
Adipocytokines and the metabolic syndrome among older persons with and without obesity: the InCHIANTI study. Clin Endocrinol (Oxf) (2010) 2.24
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab (2005) 2.18
A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. Am J Clin Nutr (2007) 2.16
Toll-like receptors in neurodegeneration. Brain Res Rev (2008) 2.15
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci (2002) 2.14
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2007) 2.08
Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. Proc Natl Acad Sci U S A (2010) 2.05
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol (2007) 2.04
Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol (2008) 2.03
Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci (2011) 2.01
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron (2004) 1.99
Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem (2002) 1.99
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res (2006) 1.97
Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci U S A (2008) 1.97
Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res Rev (2006) 1.94
Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology (2012) 1.91
Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci (2003) 1.91
Modulation of taste sensitivity by GLP-1 signaling. J Neurochem (2008) 1.89
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.86
p53 in neuronal apoptosis. Biochem Biophys Res Commun (2005) 1.85
Evidence for CALM in directing VAMP2 trafficking. Traffic (2007) 1.84
Voluntary exercise and caloric restriction enhance hippocampal dendritic spine density and BDNF levels in diabetic mice. Hippocampus (2009) 1.84
Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med (2006) 1.82
SRT1720 improves survival and healthspan of obese mice. Sci Rep (2011) 1.81
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis (2009) 1.78
Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci U S A (2004) 1.77
Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal (2010) 1.77
miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol (2010) 1.75
Membrane properties of rat embryonic multipotent neural stem cells. J Neurochem (2004) 1.73
When neurogenesis encounters aging and disease. Trends Neurosci (2010) 1.73
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J Neurochem (2002) 1.71
Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol (2010) 1.71
Age and energy intake interact to modify cell stress pathways and stroke outcome. Ann Neurol (2010) 1.68
Inducible proteopathies. Trends Neurosci (2006) 1.67
Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med (2002) 1.63
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem (2007) 1.61
Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol (2002) 1.61
hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat Struct Mol Biol (2010) 1.61
Antiparallel β-sheet architecture in Iowa-mutant β-amyloid fibrils. Proc Natl Acad Sci U S A (2012) 1.60
Sex-dependent metabolic, neuroendocrine, and cognitive responses to dietary energy restriction and excess. Endocrinology (2007) 1.59
A targeted neuroglial reporter line generated by homologous recombination in human embryonic stem cells. Stem Cells (2009) 1.59
Genome wide profiling of human embryonic stem cells (hESCs), their derivatives and embryonal carcinoma cells to develop base profiles of U.S. Federal government approved hESC lines. BMC Dev Biol (2006) 1.58
Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol (2008) 1.58
beta1 integrin maintains integrity of the embryonic neocortical stem cell niche. PLoS Biol (2009) 1.57
The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr (2013) 1.56
Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta (2010) 1.56
Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem (2008) 1.55
Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol (2005) 1.55
Toll-like receptor 3 is a negative regulator of embryonic neural progenitor cell proliferation. J Neurosci (2008) 1.55
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc Natl Acad Sci U S A (2013) 1.55
Cardioprotection by intermittent fasting in rats. Circulation (2005) 1.55
An overview of APP processing enzymes and products. Neuromolecular Med (2010) 1.54
Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. Dev Biol (2003) 1.53
Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromolecular Med (2009) 1.53
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Patterns of laminins and integrins in the embryonic ventricular zone of the CNS. J Comp Neurol (2007) 1.51
Cell-extracellular matrix interactions regulate neural differentiation of human embryonic stem cells. BMC Dev Biol (2008) 1.49
Activity-induced Notch signaling in neurons requires Arc/Arg3.1 and is essential for synaptic plasticity in hippocampal networks. Neuron (2011) 1.49
Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res (2007) 1.48